Literature DB >> 27057031

Low Prevalence of Anti-cyclic Citrullinated Peptide Antibodies in Japanese Patients with Pustulotic Arthro-osteitis.

Takenobu Ohashi1, Tomoko Hiraiwa1, Toshiyuki Yamamoto1.   

Abstract

Entities:  

Year:  2016        PMID: 27057031      PMCID: PMC4817456          DOI: 10.4103/0019-5154.177769

Source DB:  PubMed          Journal:  Indian J Dermatol        ISSN: 0019-5154            Impact factor:   1.494


× No keyword cloud information.
Sir, Pustulotic arthro-osteitis (PAO) is associated with palmoplantar pustulosis (PPP),[1] which was estimated to be nearly 10% in PPP;[2] however, data regarding its frequency are still few. Anti-cyclic citrullinated peptide (anti-CCP) antibody is rarely detected in rheumatic disorders other than rheumatoid arthritis (RA).[3] We have aimed to determine the frequency of PAO among PPP patients, and the prevalence of anti-CCP antibody in PAO. We retrospectively examined the ratio of PAO and the presence of anti-CCP antibody in 134 patients with PPP who visited our department in these 7 years. Among them, 38 patients (28.4%) were diagnosed with PAO, which was assessed by the presence of joint pain and bone scintigraphy. The age range was 23–80 years (mean age 51.7 ± 9.7) and the female-to-male ratio was 3.75:1. All patients had typical PPP limited to the palms and soles, without extra palmoplantar skin lesion involvement. Among the 38 PAO patients, anti-CCP antibody was examined in 35 cases using ELISA. Only three of them (7.9%) showed titers beyond the cut-off value (<4.5 U/ml) [Table 1]. Case 1 was a 43-year-old woman who was diagnosed with PPP 6 years ago. She had developed several tender and swollen sternoclavicular, shoulder and waist joints 2 months prior to diagnosis. Laboratory studies showed negative rheumatoid factor, increased level of anti-CCP antibody (7.1 U/ml), and anti-streptolysin O (ASO) (285 IU/ml, normal <244). Otological and dental examination did not find any focal infections. Case 2 was a 43-year-old woman with a 3-year history of intermittent pain of the right shoulder, who had vesiculopustular lesions on the palms and soles. Laboratory examination showed increased levels of white blood cell (10,600/μl), C-reactive protein (CRP: 0.38 mg/dl), and anti-CCP antibody (4.7 U/ml); however, ASO titers were within the normal range. Otological examination revealed swelling and enlargement of the tonsils. Tonsillectomy was recommended, but she selected to be treated with conservative treatment. Case 3 was a 70-year-old woman who was diagnosed with PPP 5 years ago. Pain of sternoclavicular and fifth thoracic vertebra joints appeared 3 months after the onset of PPP. CRP (0.77 mg/dl) and anti-CCP antibody (7.4 U/ml) values were elevated. Dental radiography showed chronic periodontitis.
Table 1

Analysis of characteristic features in the presence of anti-cyclic citrullinated peptide in patients with pustulotic arthro-osteitis

Analysis of characteristic features in the presence of anti-cyclic citrullinated peptide in patients with pustulotic arthro-osteitis Our results have demonstrated that more than 25% of patients with PPP have arthro-osteitis, which was much higher as compared with previous studies.[2] One reason is that our hospital is a university hospital and many PPP patients with refractory arthritis are referred; therefore, a bias may exist. Alternatively, PAO has become well known, and thus a large number of possible or occult patients are now being referred than previously. Other than RA, anti-CCP antibody becomes positive in almost 10% of patients with psoriatic arthritis[45] whereas PAO showed lower ratio of anti-CCP antibody with only low titers in this study. Serum CRP and matrix metalloproteinase-3 levels were not found to be associated with anti-CCP antibody levels in the three patients. In conclusion, we have demonstrated (i) a higher ratio of PAO in PPP (28.4%) than previous studies and (ii) a lower prevalence of anti-CCP antibody (7.9%) in PAO.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  5 in total

1.  Very low prevalence of anti-CCP antibodies in rheumatoid factor-negative psoriatic polyarthritis.

Authors:  P Pasquetti; G Morozzi; M Galeazzi
Journal:  Rheumatology (Oxford)       Date:  2008-12-24       Impact factor: 7.580

Review 2.  Pustulotic arthro-osteitis associated with palmoplantar pustulosis.

Authors:  Toshiyuki Yamamoto
Journal:  J Dermatol       Date:  2013-10-16       Impact factor: 4.005

3.  Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1162 patients.

Authors:  Judith Payet; Claire Goulvestre; Lisa Bialé; Jérôme Avouac; Julien Wipff; Chantal Job-Deslandre; Frédéric Batteux; Maxime Dougados; André Kahan; Yannick Allanore
Journal:  J Rheumatol       Date:  2014-10-01       Impact factor: 4.666

4.  Incidence of arthro-osteitis in patients with pustulosis palmaris et plantaris.

Authors:  H Sonozaki; M Kawashima; O Hongo; H Yaoita; M Ikeno; M Matsuura; K Okai; A Azuma
Journal:  Ann Rheum Dis       Date:  1981-12       Impact factor: 19.103

5.  Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis.

Authors:  Sayaka Shibata; Yayoi Tada; Mayumi Komine; Naoko Hattori; Satsuki Osame; Naoko Kanda; Shinichi Watanabe; Hidehisa Saeki; Kunihiko Tamaki
Journal:  J Dermatol Sci       Date:  2008-08-26       Impact factor: 4.563

  5 in total
  1 in total

Review 1.  Guselkumab for the Treatment of Palmoplantar Pustulosis: A Japanese Perspective.

Authors:  Toshiyuki Yamamoto
Journal:  Clin Pharmacol       Date:  2021-06-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.